Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Panitumumab

Review the clinical trials studying panitumumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-20 of 20

Testing the use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
Status: Active
Location: 173 locations
Studying Chemotherapy with or without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Status: Active
Location: 76 locations
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy versus Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial
Status: Active
Location: 56 locations
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Status: Active
Location: 13 locations
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Status: Active
Location: 6 locations
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Status: Active
Location: 5 locations
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Status: Active
Location: 11 locations
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Status: Active
Location: 5 locations
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Location: 2 locations
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Status: Active
Location: 3 locations
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Status: Active
Location: 2 locations
Hydroxychloroquine in Combination with Encorafenib and Cetuximab or Panitumumab in Treating Patients with Stage IV BRAF-Mutated Colorectal Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Botensilimab and Balstilimab with Combination Chemotherapy for the Treatment of Patients with Metastatic Microsatellite Stable Colorectal Cancer
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Status: Active
Location: 450 locations
Panitumumab-IRDye800 in Finding Cancer in Patients with Pancreatic Cancer Undergoing Surgery
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Panitumumab-IRDye800 in Diagnosing Participants with Malignant Glioma Undergoing Surgery
Status: Active
Location: 2 locations
An Imaging Agent (89Zr Panitumumab) with PET/CT for Diagnosing Primary Lesions and/or Metastases in Patients with Head and Neck Squamous Cell Carcinoma
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
111In-Panitumumab for Nodal Staging in Patients with Head and Neck Cancer
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
An Investigational Scan (89Zr-Panitumumab PET/MRI) compared to [18F]FDG-PET/MRI for the Imaging of Head and Neck Squamous Cell Carcinoma in Patients Undergoing Surgery
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
111In Panitumumab for Nodal Staging in Head and Neck Cancer
Status: Temporarily Closed to Accrual
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California